Trials / Completed
CompletedNCT03082053
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- ASLAN Pharmaceuticals · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore safety and efficacy of varlitinib administered as monotherapy in Japanese subjects with advanced or metastatic solid tumors, and administered as combination with capecitabine in Japanese subjects with advanced or metastatic biliary tract cancer. Also to evaluate pharmacokinetics (PK) of varlitinib, capecitabine and its metabolite.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | varlitinib | IMP |
| DRUG | capecitabine | Companion Medication |
Timeline
- Start date
- 2017-01-31
- Primary completion
- 2017-12-07
- Completion
- 2018-06-06
- First posted
- 2017-03-17
- Last updated
- 2018-06-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03082053. Inclusion in this directory is not an endorsement.